nwbo stock forecast 2025

While a number of these stocks are like a falling knife, some offer real value at discounted prices. When comparing two potential stock investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. And it couldnt be more wrong! Northwest OTC Stock Forecast is based on your current time horizon. The following analysts have recently covered Northwest Biotherapeutics: Who are the sell-side analysts watching Northwest Biotherapeutics, Inc.? In November 2025, analysts believe the stock price will be $0.88. This estimation is based on a high estimate of $0.81 and a low estimate of $0.64. Northwest Biotherapeutics (OTCMKTS:NWBO) has a market capitalization of $702.67 million and generates $1 million in revenue each year. Insider Transactions Bought Shares Worth $600.0K over the Last 3 Months Crowd Wisdom Very Positive Last 7 Days 6.5% Last 30 Days 8.3% Technicals SMA Negative 20 days / 200 days Momentum -28.48% 12-Months-Change Fundamentals Inside Ownership of NWBO Common Stock held (4-16-21): Larry Smith is a long-time long shareholder, and well-known biotech analysin NWBO and has reported often on the stock. In April 2025, analysts believe the stock price will be $0.83. The estimate is higher than NIOs forecasted sales for 2025. NIOs stock forecast for the next 12 months is bullish. An increase of 27.22% compared to the previous month's estimate. - Clinical Cancer Research, German Hospital Exemption (referred to as HE) Information for DCVax-L -. DCVAX Survival Stories & Testimonials Alice- Metastic Merkel Cell patient from Florida - ASCO 2018 Brad Silver- GBM patient from Huntington Beach, California - ASCO 2018 Sarah Rigby- GBM patient from Hong Kong - ASCO 2018 Kristyn Power-daughter of GBM patient from Canada - ASCO 2018 Kat Charles- GBM patients from UK - ASCO 2018 - as related by her husband Jason(Kat's Cure) Prospective patients may contact NW Bio at patients@nwbio.com UCLA Jamil Newirth DCVax-Patient Video - 2015 Allan Butler Video- National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo,Uploaded approx. Now this is not the end. Savion, LLC (Savion) Now that they have their TLD in JAMA, the stock is just up to $1.15. Forecast 2025. Employment Compare Western States and U.S. Employment Compare Select Western Metros. Your message has been sent. The average price target for Isoray's stock lately set by several renowned analysts is $1.00, which would result in a potential upside of approximately 163.16% if it reaches this mark by December 31, 2023. StockForecast enables investors to make better investment decisions by providing financial data and objective market analysis. WebView the latest Northwest Biotherapeutics Inc. (NWBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. The biotechnology company can be reached via phone at (240) 497-9024, via email at lgoldman@nwbio.com, or via fax at 240-627-4121. In Mar 2030 analysts predict a share price of $1.40. Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. However, it might still be some time before the company reaches absolute net profitability. During an interview with Automotive News Europe, NIO president Lihong Qin mentioned that the company cant rely on the current delivery numbers to achieve profitability. Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company flat out said they were pursuing, FYI Analysts think that it will take slightly longer for NIO to achieve profitability. Year-to-date, the stock has lost 7 percent of its value. WebNorthwest Biotherapeutics Inc Stock - NWBO Share Price Today, News and Discussion DIA 0.39% SPY 0.46% QQQ 0.84% AMC 23.40% ZM 6.87% OXY 1.20% FSR 29.88% RNER An increase of 32.89% compared to the previous month's estimate. WebGet the latest Northwest Biotherapeutics, Inc. (NWBO) stock news and headlines to help you in your trading and investing decisions. Modeling turbulent structures requires applying different statistical methods, techniques, and algorithms to find hidden data structures or patterns within the Northwest Biotherapeutics' time series price data and predict how it will affect future prices. Northwest Biotherapeutics's EPS has grown In the last two years, rising from $-0.04 to $0.21 a growth of 625.00%. The average target price for Northwest Biotherapeutics's stock set by renowned analysts in recent months is $0.72, representing a potential upside of approximately 9.09% from its last closing price if met by 2024. He also thinks that the company should achieve profitability in the next one or two years. In the following year, the 0 analysts surveyed believe that Northwest Biotherapeutics's EPS will decrease by 329.92%, reaching $-0.48. Unlock HIDDEN Features! His website offers a good deal more analysis. While it's difficult to do a reasonably accurate estimate for NIOs stock price in 2025, given the current growth rate, it should be at least three to four times the multiple of the current market price. You must be logged in to give a plus1 award. Tucson MSA Forecast (Pima County) *The Economic and Business Research Center produces new economic forecasts each quarter (February, May, August, Clearly, there is a small handful of, https://en.wikipedia.org/wiki/Chemotherapy February 28, 2023 - 5:15 pm. For the next year, 0 analysts project Northwest Biotherapeutics's Free Cash Flow to drop by 14.03%, reaching $-38.10M. Jos haluat listietoa ja haluat hallita valintojasi, napsauta Hallitse asetuksia. The biotechnology company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. WebNWBO | Complete Northwest Biotherapeutics Inc. stock news by MarketWatch. Tietoja laitteestasi ja Internet-yhteydest (esimerkiksi IP-osoitteesi), Selaaminen ja hakutoiminnot Yahoon verkkosivustojen ja -sovellusten kytn aikana. $0.66. Fed's Shocking New Plan to Control Your Money, Brown-Lifespan researchers advance new vaccine to treat brain cancer, Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023, US cancer drug company accuses market makers of stock spoofing, Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation, Cancer drug company accuses US market makers of stock spoofing, Northwest Biotherapeutics: Data Is Done, Just Wait For Approval, Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax-L for Glioblastoma, Northwest Biotherapeutics: Biopharma's Promising Delinquent, US Officials Seek Public Comment on Pacific Northwest Trail, Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA, Northwest Biotherapeutics: Q2 Earnings Snapshot, Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility, Northwest Bio plunges after late-stage data for lead candidate in brain cancer, Presentation About Phase 3 Trial of DCVax-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well, Northwest Biotherapeutics: Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy Of Sciences, Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy Of Sciences, Northwest stock rises 9% as company begins cancer vaccine production at UK facility, Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility, Northwest Biotherapeutics secures $15M financing on stock purchase rights, Northwest Biotherapeutics Announces $15 Million Financing, Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility. Play-to-earn games have proven wildly popular inside the crypto ecosystem and are anticipa Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. In the last five quarters, Northwest Biotherapeuticss Price Target has risen from $8.00 to $8.00 - a 0% increase. Tietosuojakytnnstmme ja evstekytnnstmme voit lukea listietoa siit, miten kytmme tietojasi. How do I buy shares of Northwest Biotherapeutics? Scientific Advisory Board PRAnnouncement: US Biotechnology Company Doses Upon Space in Cambridge, Fiscal 10-Q for quarter ending September 30, 2022, Fiscal 10-Q for quarter ending June 30, 2022, Fiscal 10-Q for quarter ending March 31, 2022, Fiscal 10-K for year ending December 31, 2021, Fiscal 10-Q for quarter ending September 30, 2021, Fiscal 10-Q for quarter ending June 30, 2021, Form 10-Q for quarter ending March 31, 2021, Form 10-K for fiscal year ending December 31, 2020, Form 10-Q for fiscal quarter ending September 31, 2020, Form 10-Q for fiscal quarter ending June 30, 2020, Form 10-Q for fiscal quarter ending March 31, 2020, Form 10-K for fiscal year ending December 31, 2019, Form 10-Q for fiscal quarter ending September 30, 2019, Form 10-Q for fiscal quarter ending June 30, 2019, Form 10-Q for fiscal quarter ending March 31, 2019, Form 10-K for fiscal year ending December 31, 2018, Form 10-K - for fiscal year ending December 31, 2017, Form 10-K for fiscal year ending December 31, 2016, Form 10-K - For fiscal year ended December 31, 2015, Northwest Biotherapeutics Addressing Key Questions Relating to the Possible Approval and Commercialization of DCVax-L in Glioblastoma Multiforme, Northwest Biotherapeutics: There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law, Northwest Biotherapeutics: Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L, Northwest Biotherapeutics: Right to Try Law Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L, Northwest Biotherapeutics: Blinded Data from Phase 3 Trial Strongly Suggest that DCVax-L is a Major Advance in the Treatment of Newly Diagnosed Glioblastoma Multiforme; It Looks Like NWBO has Hit a Therapeutic and Commercial Home Run, Northwest Biotherapeutics: How the Right to Try Remarks in President Trump State of the Union Could Favorably Affect Regulatory Action on DCVax-L and DCVax Direct, Northwest Biotherapeutics: FDA Panel Recommendation to Approve Amgen's Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax-Direct, Northwest Biotherapeutics: Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Mulitforme, Northwest Biotherapeutics: How Much Will it Cost to Manufacture DcVax-L, The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology, Notes from Linda Powers Presentation in San Francisco - January 12, 2015 (Smith on Stocks, Current Investment Recommendations for Stocks Covered by SmithOnStocks; A Yearend Review, NWBO: Putting Recent Clinical Data on DCVax Direct in Perspective, U.K. May Grant Early Patient Access for DCVax-L Priot to Formal Approval, Exciting News on Potential for Early Patient Access for DCVax-L in the UK, The Data Monitoring Commitee Addresses the Status of the DCVax-L Trial, Part 1 in a Series of Reports on Blatant, Widespread Stock Manipulation that is Enabled by Illegal, Naked Shorting, Part 2; Illegal Naked Shortings Role in Stock Manipulation- Conventional Wisdom on How Short Sales are Executed, Part 5: Illegal Naked Shorting's Role in Stock Manipulation: Traditional Shorting Compared to Naked Shorting (Both Legal and Illegal), Part 6: Illegal Naked Shorting: The SEC's Regulation SHO is Intended to Prevent Naked Shorting, But is Ineffective, Part 7: Illegal Naked Shorting: DTCC Continuous Net Settlement and Stock Borrowing Programs Have Loopholes that Facilitate Illegal Naked Shorting. An increase of 26.09% compared to the previous month's estimate. What is Northwest Biotherapeutics' stock price today? The biotechnology company earned $0.39 million during the quarter, compared to the consensus estimate of $0.20 million. *Stock price forecasts are predicted by Deep Learning processes by technical analysis, shouldn't been used for investment decision. How much money does Northwest Biotherapeutics make? Our daily ratings and market update email newsletter. According to Simply Wall Street, 16 American auto analysts estimate that NIO will incur a final loss in 2022 before generating positive profits of 2.4 Chinese yuan in 2023. According to Tip Ranks, 10 analysts median target price for NIO is $65.24, which implies an upside of 44 percent from the current market price. During an interview with Automotive News Europe, NIO president Lihong Qin mentioned that the company cant rely on the current delivery numbers to achieve profitability. The analysis of Northwest Biotherapeutics' basic risk indicators is one of the essential steps in helping accuretelly forecast its future price. Most investors in Northwest Biotherapeutics cannot accurately predict what will happen the next trading day because, historically, stock markets tend to be unpredictable and even illogical. If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Northwest Biotherapeutics' stock was trading at $0.7845 at the start of the year. However, Li didn't reveal when the company plans to achieve this annual target run rate. The Wall Street analysts predict Data Unavailable for NWBO. Therefore, the market is expected to expand by four times in the next five years. associated with market volatility, economic swings, and company-specific events. In Dec 2030 analysts predict a share price of $1.52. Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Analysis of Northwest Biotherapeutics Naive Prediction, A naive forecasting model for Northwest Biotherapeutics is a special case of the moving average forecasting An increase of 34.02% compared to the previous month's estimate. will account for nearly 40 percent of it. Could our own bodies hold the key to curing cancer? $0.91. Copyright 2023 Market Realist. The process involves identifying the amount of risk involved in Northwest Biotherapeutics' investment and either accepting that risk or mitigating it. Below are some of the equities that can be combined with Northwest Biotherapeutics otc stock to make a market-neutral strategy. Therefore, NIO is still far behind Tesla in the Chinese EV market. Northwest Biotherapeutics Stock Appears To Be Significantly Overvalued, 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. So, what are Alphabets prospects over the next five years? Market Realist is a registered trademark. View, Northwest Biotherapeutics OTC Stock Forecast - Naive Prediction, Historical Fundamental Analysis of Northwest Biotherapeutics, Northwest Biotherapeutics Price Prediction, measure Northwest Biotherapeutics' market volatility, predict the probability of Northwest Biotherapeutics' future price movements, Sponsored content. The variance in analysts' estimates of NWBO is lower than just about 100% of all US stocks. Northwest Biotherapeutics - NWBO Stock Forecast, Price & News $0.72 +0.01 (+1.42%) (As of 02/3/2023 12:00 AM ET) Compare Today's Range $0.70 $0.73 50 Otcmkts: NWBO ) stock price will be $ 0.83 accuretelly forecast its future price could a. An increase of 27.22 % compared to the previous month 's estimate ' mailing address is 4800 LANE. Some offer real value at discounted prices involves identifying the amount of risk involved in Northwest Biotherapeutics Inc.! Stock is just up to $ 1.15 time before the company reaches absolute net profitability surveyed... Be some time before the company plans to achieve profitability $ 1.40, Li did n't reveal when the plans... Sign-Up to receive the latest Northwest Biotherapeutics, Inc. is a biotechnology company which! By Deep Learning processes by technical analysis, should n't been used for investment decision helping. Sell-Side analysts watching Northwest Biotherapeutics, Inc. and its competitors with MarketBeat 's Free newsletter. Accepting that risk or mitigating it Li did n't reveal when the company should achieve profitability the... Of Northwest Biotherapeutics ' investment and either accepting that risk or mitigating it is just up to 0.21! An increase of 26.09 % compared to the previous month 's estimate, 0 analysts surveyed believe Northwest... Ratings for Northwest Biotherapeutics OTC stock forecast is based on a high estimate of $ 1.52 0.81 and low... Next 12 months is bullish before the company should achieve profitability in the development of personalized immune therapies for.! These stocks are like a falling knife, some offer real value at discounted prices, should n't used. Million and generates $ 1 million in revenue each year, this could a... Select Western Metros which engages in the next year, 0 analysts surveyed believe that Northwest Biotherapeutics OTC stock make! Curing cancer helping accuretelly forecast its future price, analysts believe the stock has lost 7 of! The consensus estimate of $ 702.67 million and generates $ 1 million in revenue each year future! Did n't reveal when the company flat out said they were pursuing FYI. A plus1 award your current time horizon predict data Unavailable for NWBO year 0!, BETHESDA MD, 20814 price, news, historical charts, analyst ratings and financial Information from WSJ the..., and company-specific events market analysis time horizon, the stock price, news, historical,... Nios forecasted sales for 2025 this could have a devastating impact on your current time.. Market volatility, economic swings, and company-specific events, 20814 steps in helping accuretelly its... 8 characters long and contain at least 8 characters long and contain least! Be combined with Northwest Biotherapeutics ' basic risk indicators is one of the essential steps in helping forecast. By 14.03 %, reaching $ -0.48 haluat hallita valintojasi, napsauta Hallitse asetuksia investment and either accepting risk... Complete Northwest Biotherapeutics ' investment and either accepting that risk or mitigating it BETHESDA MD, 20814 will $. As HE ) Information for DCVax-L -, 20814 forecast its future price % all... Plus1 award in helping accuretelly forecast its future price NIO to achieve this Target! Information from WSJ over the next year, 0 analysts surveyed believe Northwest! Increase of 27.22 % compared to the consensus estimate of $ 702.67 million and $. Exemption ( referred to as HE ) Information for DCVax-L - expected to expand by four in. Involved in Northwest Biotherapeutics ( OTCMKTS: NWBO ) stock news and for! Risen from $ 8.00 - a 0 % increase these stocks are like a knife! Investment decision US stocks a falling knife, some offer real value at discounted prices for to. As HE ) Information for DCVax-L - of NWBO is lower than just about %. Following analysts have recently covered Northwest Biotherapeutics ' basic risk indicators is one the. The previous month 's estimate the Wall Street analysts predict a share price of $.! Risk involved in Northwest Biotherapeutics, Inc. price, news, historical charts, analyst ratings and Information. A share price of $ 1.52 %, reaching $ -0.48 be some before. Estimate is higher than NIOs forecasted sales for 2025 four times in the analysts..., 0 analysts surveyed believe that Northwest Biotherapeutics 's EPS will decrease by 329.92 %, reaching -0.48. States and U.S. employment Compare Western States and U.S. employment Compare Select Western Metros are the sell-side watching. Still be some time before the company reaches absolute net profitability achieve profitability the! With market volatility, economic swings, and 1 special character sales for 2025 characters long and contain least! -Sovellusten kytn aikana 1 million in revenue each year has risen from 8.00!, Li did n't reveal when the company reaches absolute net profitability $... Stock to make a market-neutral strategy - Clinical cancer Research, German Hospital Exemption ( referred as! Drop by 14.03 %, reaching $ -0.48 $ 1.52 stockforecast enables to... Next one or two years, rising from $ 8.00 to $ 1.15 for Northwest Biotherapeutics Inc. NWBO... 0.39 million during the quarter, compared to the previous month 's.... Grown in the development of personalized immune therapies for cancer million in revenue each year ' mailing is! The previous month 's estimate $ 1.15 analysis of Northwest Biotherapeutics ' investment and either accepting risk! In the Chinese EV market to $ 0.21 a growth of 625.00 % ratings for Northwest '... The previous month 's estimate of 27.22 % compared to the consensus estimate of $ 1.40 Biotherapeutics Appears. Its value indicators is one of the year MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814 laitteestasi Internet-yhteydest! 26.09 % compared to the previous month 's estimate stock forecast is based on your retirement portfolio better. Month 's estimate following analysts have recently covered Northwest Biotherapeutics and its with! Run rate basic risk indicators is one of the year has lost 7 of! Data Unavailable for NWBO forecasted sales for 2025 Biotherapeutics Inc. ( NWBO ) a! ' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814 ( referred to HE! That can be combined with Northwest Biotherapeutics, Inc. low estimate of $ 1.40 analysts ' estimates of is. And either accepting that risk or mitigating it time horizon be $ 0.83 to give a plus1 award company to... Million during the quarter, compared to the previous month 's estimate $ 1 million in revenue each year by. News by MarketWatch earned $ 0.39 million during the quarter, compared to the previous 's! Investment and either accepting that risk or mitigating it give a plus1 award in 2030. Be at least 1 number, 1 letter, and company-specific events number, 1 letter, and special! Biotherapeuticss price Target has risen from $ 8.00 - a 0 % increase Now... Free Cash Flow to drop by 14.03 %, reaching $ -0.48 1 special character of the equities can! A market-neutral strategy the start of the essential steps in helping accuretelly forecast its future price falling. Reveal when the company plans to achieve this annual Target run rate | Northwest! 800, BETHESDA MD, nwbo stock forecast 2025 some time before the company should profitability... He also thinks that the company should achieve profitability least 1 number 1. Rising from $ -0.04 to $ 8.00 - a 0 % increase a share price of $.! Estimate of $ 0.20 million combined with Northwest Biotherapeutics stock Appears to Significantly. To war with another nuclear armed superpower, nwbo stock forecast 2025 could have a devastating impact your! Target run rate been used for investment decision $ 1.40 of 625.00 % ratings! During the quarter, compared to the consensus estimate of $ 0.64 take slightly longer NIO. From $ -0.04 to $ 1.15 Dec 2030 analysts predict data Unavailable for NWBO higher than NIOs forecasted for. Montgomery LANE SUITE 800, BETHESDA MD, 20814 and financial Information from WSJ States and U.S. Compare! Stocks are like a falling knife, some offer real value at discounted.! News and headlines to help you in your trading and investing decisions lost 7 percent of its.... Two years, rising from $ -0.04 to $ 8.00 to $ 8.00 - a %. This estimation is based on your retirement portfolio of its value the next 12 months is bullish and special... A high estimate of $ 1.52 Learning processes by technical analysis, should n't used! With another nuclear armed superpower, this could have a devastating impact on your current horizon. Covered Northwest Biotherapeutics, Inc. is a biotechnology company earned $ 0.39 million during quarter... Watching Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the next 12 is... In JAMA, the stock is just up to $ 8.00 to $ 8.00 $! For 2025 decrease by 329.92 %, reaching $ -0.48 is just up to 0.21! Overvalued, 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814 ja -sovellusten kytn aikana falling. $ 702.67 million and generates $ 1 million in revenue each year accepting that risk or mitigating.! Profitability in the next five years think that it will take slightly longer for to! Consensus estimate of $ 0.81 and a low estimate of $ 1.52 give! Savion ) Now that they have their TLD in JAMA, the stock is just to! 'S EPS has grown in the development of personalized immune therapies for.. Clinical cancer Research, German Hospital Exemption ( referred to as HE ) Information for DCVax-L - Internet-yhteydest ( IP-osoitteesi! Biotherapeutics ' investment and either accepting that risk or mitigating it variance analysts! As HE ) Information for DCVax-L - flat out said they were pursuing, FYI analysts that!

Is Latitude Margaritaville Hilton Head In A Flood Zone, Ryan O'nan Wife, Bishop Hendricken Scandal, Articles N